← Back to Clinical Trials
Recruiting NCT05765786

NCT05765786 Diagnosing Variable Primary Aldosteronism.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05765786
Status Recruiting
Phase
Sponsor Queen Mary University of London
Condition Primary Aldosteronism
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2023-02-24
Primary Completion 2027-07-24

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2023-02-24 with a primary completion date of 2027-07-24.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to see if there is a cyclical or exaggerated diurnal variation in aldosterone production in people with Primary Aldosteronism.

Eligibility Criteria

Inclusion Criteria: * People with clinically suspected PA but have not met criteria for diagnosis. Suspicion based on low-renin (renin activity \<0.5 nmol/h/L or renin mass \<5 ng/L), plasma sodium \> 140mmol/L or plasma potassium \< 4mmol/L. * Patients who have been diagnosed with PA and had previous aldosterone samples \<277 pmol/L, a level which would normally not qualify for confirmatory testing. * Patients with aldosterone results done at different times that indicate variability in production. * Willing to consent and participate in the study. Exclusion Criteria: * Inability to withdraw β-adrenoceptor antagonist therapy for 2 weeks. * People on end of life treatment.

Contact & Investigator

Central Contact

Yun Ni Lee

✉ y.n.lee@qmul.ac.uk

📞 +442078827275

Principal Investigator

William Drake, Prof

PRINCIPAL INVESTIGATOR

Queen Mary University of London

Frequently Asked Questions

Who can join the NCT05765786 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Primary Aldosteronism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05765786 currently recruiting?

Yes, NCT05765786 is actively recruiting participants. Contact the research team at y.n.lee@qmul.ac.uk for enrollment information.

Where is the NCT05765786 trial being conducted?

This trial is being conducted at London, United Kingdom.

Who is sponsoring the NCT05765786 clinical trial?

NCT05765786 is sponsored by Queen Mary University of London. The principal investigator is William Drake, Prof at Queen Mary University of London. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology